Waters' (WAT) "strong performance" in Q3 and forward guidance support its rating thesis, RBC Capital Markets said in a note emailed Wednesday.
The company reported fiscal Q3 non-GAAP earnings Tuesday of $4.10 per share on revenue of $1.77 billion. Analysts polled by FactSet expected EPS of $4 on revenue of $1.75 billion.
Results from the recently acquired Becton Dickinson Life Sciences businesses were intentionally in line, but several of its initiatives have upside, RBC analysts said. The segment's pricing traction is improving, localization in China came in earlier than planned, and placements of BD COR are accelerating, the analysts noted.
Aside from the turnaround opportunity for the Becton Dickinson businesses, further positive factors for Waters include the upside optionality from its emerging role as a sector consolidator and meaningful sales exposure to durable tailwinds in drug manufacturing, according to the note.
RBC maintained the company's stock rating at outperform and raised the price target to $525 from $475.
Price: 466.40, Change: +6.50, Percent Change: +1.41
Comments